21:29 , Jun 21, 2019 |  BioCentury  |  Emerging Company Profile

Arcutis: Reformulating dermatology

Arcutis Inc. is using its founders’ topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren’t eligible for biologics. Frazier Healthcare launched the company in 2016...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
01:29 , Apr 15, 2017 |  BioCentury  |  Strategy

WAC-a-mol

While investors, media and even some payers have been touting the pricing of three recently launched drugs as sensible, it is not clear whether the lower-than-expected list prices will actually reduce costs to payers. But...
22:20 , Jan 6, 2017 |  BioCentury  |  Finance

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
22:05 , Dec 16, 2016 |  BioCentury  |  Regulation

Blip or dip?

In a ritual held each year a couple of weeks before the winter solstice, pundits pore over FDA’s new drug approval statistics and use them to pontificate about the health of the biopharma industry and...
23:19 , Dec 15, 2016 |  BC Week In Review  |  Clinical News

Eucrisa regulatory update

FDA approved an NDA from Pfizer for Eucrisa crisaborole 2% ointment to treat mild to moderate atopic dermatitis in patients ages ≥2. Pfizer said the company plans to launch Eucrisa by the end of January...
01:36 , Dec 15, 2016 |  BC Extra  |  Company News

FDA approves Pfizer eczema drug Eucrisa

FDA approved Eucrisa crisaborole (formerly AN2728 ) from Pfizer Inc. (NYSE:PFE) to treat mild to moderate atopic dermatitis in patients aged two and older. Pfizer spokesperson Steven Danehy said the company plans to launch Eucrisa...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Anacor, Pfizer deal

Pfizer will acquire Anacor for $99.25 per share in cash, or about $5.2 billion net of cash. The price is a 55% premium to Anacor’s close of $64.03 on May 13, before the deal was...
01:11 , May 17, 2016 |  BC Extra  |  Top Story

Pfizer acquiring Anacor for $5.2B

Pfizer Inc. (NYSE:PFE) will acquire Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), giving it atopic dermatitis candidate crisaborole ( AN2728 ). The pharma will pay $99.25 per share in cash, or about $5.2 billion. The price is a...